

Testing the Use of AMG 510 (Sotorasib) and Panitumumab as a Targeted Treatment for KRAS G12C Mutant Solid Tumor Cancers (A ComboMATCH Treatment Trial)

NCT05638295

Status	RECRUITING
Phase	Phase 2
Sponsor	National Cancer Institute (NCI)
Enrollment	105 participants

Key Eligibility Criteria

Inclusion (33)

- Patient must have enrolled onto EAY191 and must have been given a treatment assignment to ComboMATCH to EAY191-E5 based on the presence of an actionable mutation as defined in EAY191
- Patient must be enrolled on the ComboMATCH Registration Protocol (EAY191) at the time of registration/randomization to the EAY191-E5 study
- Patient must be \geq 18 years of age
- Patient must have a KRAS G12C alteration as determined by the ComboMATCH screening assessment
- Patient must have disease that can be safely biopsied and agree to a pre-treatment biopsy or have tissue available from within 12 months prior to the date of registration on the ComboMATCH Registration Trial (EAY191-E5)

... and 28 more (see full listing online)

Locations (182 total)

University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
University of South Alabama Mitchell Cancer Institute, Mobile, Alabama, United States
The Angeles Clinic and Research Institute - West Los Angeles Office, Los Angeles, California, United States
... and 179 more locations